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Abstract 38 
Background: Two major constituents of cannabis are D9-tetrahydrocannabinol (THC) and 39 
cannabidiol (CBD). THC is the main psychoactive component; CBD may buffer the user 40 
against the harmful effects of THC.  41 
Aims: We examined the effects of two strains of cannabis and placebo on the human brain’s 42 
resting-state networks using fMRI.  43 
Methods: 17 healthy volunteers (experienced with cannabis, but not regular users) 44 
underwent three drug treatments and scanning sessions. Treatments were cannabis 45 
containing THC (Cann-CBD; 8mg THC), cannabis containing THC with CBD (Cann+CBD; 8mg 46 
THC + 10mg CBD), and matched placebo cannabis. Seed-based resting-state functional-47 
connectivity analyses were performed on three brain networks: the default mode (DMN; 48 
defined by positive connectivity with the posterior cingulate cortex: PCC+), executive control 49 
(ECN; defined by negative connectivity with the posterior cingulate cortex: PCC-) and 50 
salience (SAL; defined by positive connectivity with the anterior insula: AI+) network.  51 
Results: Reductions in functional connectivity (relative to placebo) were seen in the DMN 52 
(PCC+) and SAL (AI+) networks for both strains of cannabis, with spatially dissociable effects. 53 
Across the entire salience network (AI+) Cann-CBD reduced connectivity relative to 54 
Cann+CBD. The PCC in the DMN was specifically disrupted by Cann-CBD and this effect 55 
correlated with subjective drug effects including feeling ‘stoned’, and ‘high’. 56 
Conclusions: THC disrupts the default mode network and the PCC is a key brain region 57 
involved in the subjective experience of THC intoxication. CBD restores disruption of the 58 
salience network by THC, which may explain its potential to treat disorders of salience such 59 
as psychosis and addiction. 60 
 61 
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Introduction 66 
Cannabis has been used by humans for thousands of years for medical, spiritual, and 67 
recreational purposes. Two of the main psychoactive ingredients of cannabis are D9-68 
tetrahydrocannabinol (THC) and cannabidiol (CBD). As well as making people “stoned”, THC 69 
produces amnestic, anxiogenic, and psychotomimetic effects (including perceptual 70 
distortions, paranoia, disruptions of cognitive functions, and euphoria; D’Souza et al., 2004), 71 
by acting as an agonist at endocannabinoid 1 (CB1) receptors (Pertwee, 2008). CBD’s effects 72 
have been less well studied, but early findings suggest it may have somewhat opposite 73 
effects, being anti-psychotic (Leweke et al., 2012), and perhaps anxiolytic (Bergamaschi et 74 
al., 2011). CBD is non-intoxicating,  and has a more complex neuropharmacological profile, 75 
including reducing the cellular reuptake and hydrolysis of anandamide, antagonism of the 76 
orphan receptor GPR55 and the 5-HT1A receptor, and  antagonism of the CB1 receptor with 77 
a low affinity (Pertwee, 2008). 78 
 79 
THC is also largely responsible for providing many of the subjective effects of intoxication 80 
that recreational users seek (Curran et al., 2002). Concern has recently been raised about 81 
the high levels of THC found in modern cannabis, alongside  minimal, if any, levels of CBD 82 
(ElSohly et al., 2016; Niesink et al., 2015). This high-strength cannabis (often referred to as 83 
‘skunk’) is popular with users, but is also hypothesised to be responsible for the dramatic 84 
increase in reporting of cannabis-related health issues in recent years; most notably 85 
addiction, and cannabis-induced psychosis (Di Forti et al. 2009; Freeman et al., 2018; 86 
Freeman and Winstock, 2015). Because of its putatively opposing psychological and 87 
pharmacological effects, cannabis that contains higher levels of CBD may be a safer option 88 
on the basis that CBD may buffer the user against the main negative effects of THC (Curran 89 
et al., 2016; Englund et al., 2013; Hindocha et al., 2015; Niesink and van Laar, 2013). 90 
 91 
As cannabis transitions to legal/decriminalised status in many jurisdictions, understanding 92 
the neural effects of different strains of cannabis (with different levels of THC and CBD) is 93 
now a priority for public health. Functional Magnetic Resonance Imaging (fMRI) is a popular 94 
method for indexing drug effects (Bourke and Wall, 2015; Iannetti and Wise, 2007), with 95 
resting-state fMRI (Fox and Raichle, 2007; Luca et al., 2006) particularly useful, as it can 96 
derive results from multiple brain systems, and provides a sensitive index of drug effects 97 
(e.g. Carhart-Harris et al., 2015; Kaelen et al., 2016). The DMN is perhaps the most 98 
prominent and well-studied resting-state network and its activity increases in periods of 99 
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wakeful rest, and during internally-focussed states such as autobiographical memory 100 
retrieval (Buckner et al., 2008). In contrast, its complementary network (the Executive 101 
Control Network, or ECN) is most active when subjects are engaged on an external task (Fox 102 
et al., 2005). The Salience network (Seeley et al., 2007) is involved in the detection of 103 
emotional and sensory stimuli, and may be responsible for the switch between internally-104 
focussed states supported by the DMN, and externally-focussed states supported by the ECN 105 
(Goulden et al., 2014). Unfortunately the differential effects of herbal cannabis with 106 
different concentrations of THC and CBD on these networks is largely unknown. Most 107 
previous neuroimaging studies using an acute drug challenge have focussed on the effects of 108 
synthetic THC (e.g. Klumpers et al., 2012). Bossong and colleagues (2013) demonstrated 109 
acute disruptive effects of synthetic THC on the Default Mode Network (DMN), but in the 110 
context of an executive function task, with less effect on task-related brain regions. A recent 111 
study has also found similar results (reduction in default mode function) using the CB1 112 
neutral antagonist tetrahydrocannibivarin (THCv; Rzepa et al., 2016). Another set of studies 113 
has compared oral synthetic THC and CBD, and found opposite effects of the two treatments 114 
on a range of functional and perceptual tasks, including differing effects on brain regions 115 
involved in salience processing (Bhattacharyya et al., 2010, 2012, 2014; Winton-Brown et al., 116 
2011). Further studies have focussed on other resting-state connectivity networks, including 117 
corticostriatal connectivity (Grimm et al., 2018; Ramaekers et al., 2016), and the insula and 118 
frontal lobe (van Hell et al., 2011) 119 
 120 
Our aim was to use fMRI to directly investigate the effects of different strains of herbal 121 
cannabis on resting-state functional connectivity, using one strain containing high levels of 122 
THC but negligible levels of CBD (Cann-CBD), and another strain containing more balanced 123 
levels of THC and CBD (Cann+CBD). Both treatments were matched for total THC content, 124 
and were compared to placebo cannabis (containing neither compound), which was well 125 
matched for terpene content and therefore had the same smell and appearance as active 126 
treatments. We hypothesized that the Cann-CBD treatment would induce more disruption 127 
(i.e. reductions in functional connectivity measures) in resting-state networks than the 128 
Cann+CBD strain. 129 
   130 
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Methods 131 
 132 
Design and Participants 133 
A randomised, crossover, placebo-controlled, double-blind design was used to compare 134 
cannabis containing both THC and CBD (Cann+CBD), cannabis containing THC but no CBD 135 
(Cann-CBD), and matched placebo cannabis containing neither compound. Participants were 136 
randomly assigned to one of three treatment order conditions, based on a Latin Square 137 
design. In order to eliminate potential carry-over effects, scanning sessions were separated 138 
by wash-out periods of at least one week, which is more than three times the elimination 139 
half-life of THC (Hindocha et al., 2014, 2015). Additional data from this study have been 140 
published elsewhere (Freeman, Pope, Wall, Bisby, Luijten, Hindocha, Mokrysz, Lawn, 141 
Bloomfield, et al., 2017; Lawn et al., 2016). 142 
 143 
Participants were 17 (9 female) healthy volunteers. Inclusion criteria were age between 18-144 
70, cannabis use ≤3 times per week and ≥4 times in the last year, and fluency in English. 145 
Exclusion criteria were previous negative experiences with cannabis, alcohol use >5 times 146 
per week, other illicit drug use > twice per month, current/history of psychosis, 147 
current/history of psychosis in an immediate family member, colour blindness, any other 148 
physical health problems deemed clinically significant, and general MRI contraindications. 149 
The mean age of subjects was 26.2 (SD = 7.1), and they reported using cannabis an average 150 
of 8.1 days per month (SD = 5.5). Full demographic data and information about current drug 151 
use for the group is provided in the supplementary material (Table S1). The study was 152 
approved by the University College London (UCL) Ethics Committee and was conducted in 153 
accordance with the Declaration of Helsinki. Subjects provided written informed consent, 154 
were reimbursed £7.50/hour, and could also win extra money via completion of other tasks 155 
(not reported here). 156 
 157 
 158 
Drug Administration 159 
Cannabis was sourced from Bedrocan (The Netherlands) and stored in foil-sealed pouches at 160 
-20°C, and then at ambient temperature immediately prior to administration. All three 161 
varieties of cannabis were well matched in terms of appearance and smell, and the same 162 
amount of cannabis (133.4mg) was administered in each session (see (Lawn et al., 2016) for 163 
full details of the dosing regime). Target doses were 8mg THC and 10 mg CBD (in the 164 
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Cann+CBD treatment) and 8mg THC (in the Cann-CBD treatment). This is equivalent to 165 
roughly 25% of an average UK joint, assuming a roughly 10% THC content (Freeman et al., 166 
2014). Doses were vaporized in a Volcano Medic Vaporizer (Storz and Bickel, Tuttlingen, 167 
Germany) at 210ºC, and the resulting vapour was collected in two balloons. These were 168 
inhaled sequentially at the participants’ own pace, with each inhalation held in the lungs for 169 
eight seconds, until the balloons were empty. This administration protocol using a vaporizer 170 
and inhaled balloons was similar to previous studies that have produced clear behavioural 171 
and brain effects with similar dosages (Bossong et al., 2009; Hindocha et al., 2015; Mokrysz 172 
et al., 2016). 173 
 174 
Procedure 175 
Participants completed a baseline/screening session consisting of task training (outside of 176 
the MRI scanner), video training for the vaporizer protocol, heart rate and blood pressure 177 
readings, and trait measures (BDI, TEPS, SDS, drug history). Subjects were asked to refrain 178 
from drug and alcohol use for 24 hours before each test session, and each session began 179 
with a urine screen to confirm recently reported drug use. Approximately 30 minutes 180 
following drug administration, participants were situated in the MRI scanner, and completed 181 
an approximately one-hour scanning session. The scanning session included standard 182 
anatomical scans, a music listening task (Freeman et al., 2017) a memory task, and a resting-183 
state scan (reported herein). Ratings of subjective effects using Visual Analogue Scales (VAS) 184 
were administered immediately before the drug dosing, approximately five minutes after 185 
drug dosing, and approximately 90 minutes after drug dosing (after the MRI scan). These 186 
consisted of the following items: “Alert”, “Happy”, “Anxious”, “Paranoid”, “Mentally 187 
impaired”, “Stoned”, “High”, “Feel drug effect”, “Like drug effect”, “Dry mouth”, “Enhanced 188 
colour perception”, “Enhanced sound perception”, “Want to listen to music”, “Want food”, 189 
and “Want more cannabis”. Analysis of the VAS scores has been reported elsewhere 190 
(Freeman et al., 2017; Lawn et al., 2016). Following the MRI scan subjects completed a 191 
number of additional behavioural tests and questionnaires; these are also fully reported 192 
elsewhere (Lawn et al., 2016). 193 
 194 
 195 
MRI Acquisition and Analysis 196 
Data were acquired on a Siemens Avanto 1.5T MRI scanner (Erlangen, Germany) using a 32-197 
channel phased-array head-coil. At the beginning of the scan session standard MPRAGE 198 
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(Magnetization Prepared RApid Gradient Echo) anatomical scans were acquired (TR = 199 
2730ms; TE = 3.57ms; matrix = 176 x 256 x 256; 1mm isotropic voxels; flip angle = 7°; 200 
bandwidth = 190Hz/pixel; parallel imaging acceleration factor = 2). The resting-state 201 
functional images were acquired with a gradient-echo Echo-Planar Imaging (EPI) sequence 202 
with a repetition time (TR) of 2800 ms, 32 slices with 3.2mm isotropic voxels, an echo-time 203 
(TE) of 43ms, and a flip-angle of 90°. A total of 260 volumes were acquired, for a total scan 204 
length of 12 minutes and 8 seconds.  205 
 206 
All analyses were performed with FSL 5.0.4 (except where noted below). Pre-processing of 207 
the data consisted of head-motion correction, spatial smoothing with a 6mm FWHM (Full-208 
Width, Half-Maximum) Gaussian kernel, high-pass temporal filtering (100s), and registration 209 
to a standard template (MNI152). Anatomical data were skull-stripped with FSL’s Brain 210 
Extraction Tool (BET) and segmented into grey/white matter and CSF (Cerebro-Spinal Fluid) 211 
masks using FMRIB’s Automated Segmentation Tool (FAST). 212 
 213 
Seed-based functional connectivity analyses were conducted using the general 214 
methodological approach previously used by Demetriou et al. (2018) and (Comninos et al., 215 
2018). Regions Of Interest (ROIs) were defined in the posterior cingulate cortex (PCC) and 216 
anterior insula (AI) as seed-regions (see supplementary figure S1). These regions were 217 
derived from automated meta-analytic data on http://neurosynth.org/, using the ‘default 218 
mode’ and ‘salience’ terms. These meta-analysis maps were thresholded, and the PCC and 219 
anterior insula clusters were isolated and binarised for use as image masks. These masks 220 
were co-registered to each individual participant’s functional image space, thresholded (at 221 
0.5), and time-series from these resulting mask images were extracted and used as the 222 
regressor of interest in separate first-level analysis models. Additional regressors modelled 223 
noise effects and were derived from the mean white matter and CSF anatomical masks (also 224 
co-registered to individual functional space, and thresholded at 0.5). Group-level analyses 225 
used FSL’s FLAME-1 mixed-effects model and results were thresholded at Z > 2.3 (p < 0.05, 226 
cluster-corrected for multiple comparisons). Separate group-level models were produced in 227 
order to model mean functional connectivity effects (all subjects, all scans) and voxelwise 228 
comparisons between the three treatment conditions. The group mean functional 229 
connectivity results were used to produce image masks (thresholded at Z=5) in order to 230 
quantify the treatment effects across the entire network(s). 231 
 232 
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This procedure of defining resting-state networks using a single seed-region is an established 233 
method (Comninos et al., 2018; Passow et al., 2015; Seeley et al., 2007), however networks 234 
can also be defined by Independent Components Analysis (ICA), multi-seed region analysis, 235 
and various other more exotic methods (see Cole et al., 2010 for a review). The single-seed 236 
region method has benefits in that it is strongly hypothesis driven, and generally produces 237 
robust patterns of connectivity, which bear a strong relationship to the canonical networks 238 
derived from large-scale ICA analyses (e.g. Biswal et al., 2010; Smith et al., 2009). However, 239 
this is dependent on the selection of a suitable seed-region, and the main drawback of this 240 
method is potential bias and/or error in region selection. For this reason, and for the sake of 241 
absolute precision, we will henceforth refer to these networks as DMN (PCC+; positive 242 
connectivity with the PCC), ECN (PCC-; negative connectivity with the PCC), and the salience 243 
network or SAL (AI+; positive connectivity with the anterior insula).  244 
 245 
Significant clusters resulting from these whole-brain analyses were defined as ROIs, and data 246 
from these ROIs was used to perform correlation analyses with VAS measures rated outside 247 
the scanner. A False Discovery Rate (FDR) correction for multiple comparisons (Benjamini 248 
and Hochberg, 1995) was applied to the p values resulting from these analyses within each 249 
brain region.   250 
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Results 251 
 252 
Seed-based functional connectivity analyses 253 
Group mean (all subjects, all scans) analyses of seed-based functional connectivity showed 254 
brain networks similar to those reported previously for the DMN and ECN (using the PCC 255 
seed region; e.g. Fox et al., 2005) and the salience network (using the anterior insula seed 256 
region; e.g. Seeley et al., 2007). There was also strong concordance between the observed 257 
networks and the meta-analytic maps available on http://neurosynth.org/ from which the 258 
original seed-regions were derived. These group mean connectivity maps are included in the 259 
supplementary material (see Figure S3).  260 
 261 
Treatment effects on the mean connectivity across the entire network(s) are shown in Figure 262 
1. Both treatments (relative to placebo) had similarly disruptive effects on the DMN (PCC+) 263 
network (Cann+CBD: t[16] = 2.46, p = 0.026; Cann-CBD: t[16] = 2.22, p = 0.041), and non-264 
significant effects on the ECN (PCC-) network (all p > 0.1). In the SAL (AI+) network the Cann-265 
CBD treatment caused a reduction in connectivity (relative to Cann+CBD; t[16]=3.18, p = 266 
0.005), however neither of the two drug treatments were significantly different to placebo. 267 
 268 
Figure 1. Treatment effects on the mean connectivity across the three networks; 269 
Default Mode Network (DMN; PCC+, left), Executive Control Network (ECN; PCC-, 270 
middle) and the Salience Network (SAL, AI+, right).  * p < 0.05, ** p < 0.005. Error 271 
bars are standard errors.  272 
 273 
Voxelwise comparison of the treatment conditions revealed that in the DMN (PCC+) 274 
network, both strains caused a decrease in functional connectivity in the right inferior 275 
parietal lobe, and the hippocampus, though effects were restricted to the right 276 
hippocampus for the Cann-CBD strain, and were bilateral for the Cann+CBD strain. There 277 
was also a specific effect of Cann-CBD cannabis in the PCC/precuneus region (see Figure 2). 278 
 279 
 280 
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 281 
Figure 2. Drug treatment effects on the DMN (PCC+) network. All contrasts are 282 
placebo > drug, therefore significant (Z = 2.3, p < 0.05, cluster corrected for multiple 283 
comparisons) clusters represent relative decreases in functional connectivity in the 284 
drug condition. The Cann+CBD treatment session is shown in the blue scale, and the 285 
Cann-CBD treatment session is shown in the green scale. 286 
 287 
Disruptions of functional connectivity in the ECN (PCC-) network induced by both active 288 
treatments were relatively minimal, with effects restricted to the left frontal lobe. The two 289 
strains produced spatially dissociable effects however, with Cann+CBD showing most effect 290 
in the inferior frontal gyrus, and Cann-CBD showing most effect in ventro-lateral prefrontal 291 
cortex. See Figure 3. 292 
 293 
 294 
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 295 
Figure 3. Drug treatment effects on the ECN (PCC-) network. All contrasts are 296 
placebo > drug, therefore significant (Z = 2.3, p < 0.05, cluster corrected for multiple 297 
comparisons) clusters represent relative decreases in functional connectivity in the 298 
drug condition. The Cann+CBD treatment session is shown in the blue scale, and the 299 
Cann-CBD treatment session is shown in the green scale. 300 
 301 
Effects on the SAL (AI+) network were also strongly dissociated, with only minimal disruption 302 
seen for the Cann+CBD treatment in the left hemisphere post-central gyrus and the frontal 303 
pole. However the Cann-CBD strain produced widespread disruptions (reductions) in 304 
functional connectivity in left frontal (dorsolateral prefrontal cortex, ventrolateral prefrontal 305 
cortex) and temporal (anterior superior temporal gyrus, posterior inferior temporal gyrus) 306 
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regions. Also present in the Cann-CBD treatment were bilateral effects in the putamen, the 307 
ventromedial prefrontal cortex, and the frontal pole. See Figure 4. 308 
 309 
 310 
Figure 4. Drug treatment effects on the SAL (AI+) network. All contrasts are placebo 311 
> drug, therefore significant (Z = 2.3, p < 0.05, cluster corrected for multiple 312 
comparisons) clusters represent relative decreases in functional connectivity in the 313 
drug condition. The Cann+CBD treatment session is shown in the blue scale, and the 314 
Cann-CBD treatment session is shown in the green scale. 315 
 316 
Group-level voxelwise comparisons between the two active treatment conditions (Cann-CBD 317 
vs. Cann+CBD) produced no significant clusters, in any of the three networks. Likewise there 318 
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were no significant clusters when increases in functional connectivity (relative to placebo) 319 
were examined; all observed effects were decreases, relative to placebo. 320 
 321 
Each of the major clusters resulting from the analyses of treatment effects was defined as a 322 
ROI, and response amplitude data was extracted from these regions in order to perform 323 
cross-subject correlations with self-report response measures performed outside the 324 
scanner, immediately following the scan session. The majority of significant (FDR-corrected) 325 
correlations involved the Cann-CBD treatment and the region in the PCC that showed 326 
specific effects for this treatment in the DMN (PCC+) network analysis. The extent of 327 
disruption of connectivity in the PCC showed strong correlations with a number of subjective 328 
measures: ‘Stoned’, ‘High’, ‘Feel drug effect’, ‘Dry mouth’, ‘Enhanced colour perception’, and 329 
‘Enhanced sound perception’. See Figure 5 for scatterplots and correlation coefficients for 330 
this region and treatment. One additional significant correlation involved the frontal pole 331 
region seen in the salience network analysis; this region significantly negatively correlated 332 
with feelings of paranoia, again specifically in the Cann-CBD treatment (r = -0.674, p(FDR) = 333 
0.048). All other correlations were non-significant (p > 0.05, FDR-corrected). See 334 
supplementary material for full tables of the correlation results. 335 
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 336 
Figure 5. Correlations between the specific effect of Cann-CBD on the PCC in the 337 
DMN (PCC+) network analysis and Visual Analogue Scale (VAS) measures collected 338 
immediately after the MRI scanning session (approximately 90 minutes post-dosing). 339 
Correlations between the effect of Cann-CBD cannabis on the PCC cluster (top row, 340 
surface and slice-based visualisations of the region) and six separate VAS scales; 341 
feeling ‘stoned’, feeling ‘high’, feeling the drug effect, having a dry mouth, 342 
experiencing enhanced colour and sound perception. Pearson’s r values and False 343 
Discovery Rate (FDR) corrected p values are included for each plot. See 344 
supplementary information for full statistical tables of r, p, and FDR-corrected p 345 
values. 346 
347 
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Discussion 348 
We have shown that cannabis reduces functional connectivity in a number of canonical 349 
resting-state brain networks, and furthermore that different strains of cannabis have 350 
dissociable effects on these networks. Effects on the DMN (PCC+) and SAL (AI+) networks are 351 
extensive, while effects on the ECN (PCC-) network appear relatively minor. Furthermore, 352 
effects of the THC without CBD strain (Cann-CBD) are more widespread in the DMN (PCC+) 353 
and SAL (AI+) networks, and the specific effect of this strain in the PCC region of the DMN 354 
(PCC+) is highly associated with classic subjective measures of the drug effect such as feeling 355 
‘stoned’ and ‘high’ and having enhanced perception of both sounds and colours. Specific 356 
effects of the Cann-CBD strain were also seen in left frontal and temporal regions in the 357 
salience network.  358 
 359 
These findings are broadly consonant with the few previous reports using cannabinoids and 360 
resting-state fMRI. One recent study (Rzepa et al., 2016) used the CB1 neutral antagonist 361 
THCV, and showed a pattern of disruption of the DMN strikingly similar to the present data, 362 
with selective effects in the PCC and right hemisphere parietal lobe. Another previous 363 
resting-state study (Klumpers et al., 2012) which used pure synthetic THC  showed effects in 364 
the visual cortex, frontal lobe, cerebellum, and sensorimotor regions, though notably, in this 365 
study THC instead appeared to increase connectivity measures in the majority of regions. A 366 
third previous study (Bossong et al., 2013) also showed less deactivation (relative to 367 
placebo) in the DMN (particularly in the PCC) with pure synthetic THC treatment during a 368 
cognitive task. This deactivation of the PCC was also negatively correlated with task 369 
performance, suggesting that higher activation levels of the PCC during the task had a 370 
deleterious effect on task performance.  371 
 372 
What these previous studies and the present data clearly demonstrate is that the PCC is a 373 
key brain structure involved in the neuropsychopharmacological effects of cannabinoids 374 
(including THCV, and pure THC). This is further reinforced by investigations using CB1-active 375 
radioligands and Positron Emission Tomography (PET) to image CB1 receptor distribution 376 
and function, which have shown a very high density of CB1 receptors in the PCC, visual 377 
cortex, putamen, and temporal lobe regions (Burns et al., 2007). A further PET study 378 
demonstrated that CB1 receptor distributions were down-regulated in daily cannabis 379 
smokers, most notably in the PCC/precuneus, visual cortex, and temporal and frontal lobes, 380 
and that this down-regulation was reversible after four weeks of abstinence (Hirvonen et al., 381 
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2012). This is also consistent with findings that show reductions in endogenous cannabinoids 382 
in chronic cannabis use (Morgan et al., 2013). One other recent study (Orr et al., 2013) on 383 
cannabis dependent adolescents demonstrated increased PCC connectivity in the default 384 
mode network (while abstinent). These findings taken together therefore suggest a possible 385 
mechanism for the effect of cannabinoids (particularly THC) on the PCC. The acute effect is 386 
to disrupt PCC function (as demonstrated by (Bossong et al., 2013; Rzepa et al., 2016), and 387 
the present data), and regular use may lead to down-regulation of CB1 receptors in the 388 
region (Hirvonen et al., 2012). This longer-term impairment of PCC function may then lead to 389 
compensatory hyperactivation/hyperconnectivity of the PCC in long-term users (as seen in 390 
Orr et al., 2013). This proposed mechanism, while plausible, rests on results from only a few 391 
studies, and therefore requires much further substantiation. In addition, how these 392 
potential effects on the PCC are precisely related to issues associated with long-term use 393 
such as dependence, and cannabis-induced psychosis is a key question for future research. 394 
 395 
In the present data, the PCC also emerged as the only region that was significantly related to 396 
subjective effects of the drug, and this was only true when administered cannabis which 397 
contained no CBD. This lends support to an emerging view that the effects of THC and CBD 398 
are in many ways oppositional, and that CBD may serve to buffer the user somewhat against 399 
the harmful long-term effects of THC (Curran et al., 2016; Demirakca et al., 2011; Morgan et 400 
al., 2012; Morgan and Curran, 2008; Niesink and van Laar, 2013; Yücel et al., 2016). The 401 
present data further suggest that CBD may also buffer the user against the acute effects of 402 
THC on the PCC and abolishes the relationship between functional disruption in this region 403 
and the subjective effects of intoxication. Adding this element to the potential physiological 404 
mechanism outlined above, dampening of the acute effects of THC by CBD may lead to less 405 
overall down-regulation of CB1 receptors with long-term use, and lessen the probability of 406 
the user developing dependence and/or psychosis (Morgan et al., 2010, 2012; Morgan and 407 
Curran, 2008). Two cross-sectional studies to date have also reported associations between 408 
chronic CBD exposure and protection of the hippocampus (Demirakca et al., 2011; Yücel et 409 
al., 2016), also a key DMN region with high CB1 receptor density. 410 
 411 
The salience network has been proposed (Goulden et al., 2014; Sridharan et al., 2008) as the 412 
mechanism that switches between higher activity in the DMN (reflecting an internal focus, 413 
or a resting, relaxed state) and higher activity in the ECN (reflecting active engagement with 414 
a task, or focussed attention). Efficient function of the salience network therefore supports 415 
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the functions of the other networks in an important manner. Disruption of the salience 416 
network may therefore also underlie some of the acute phenomenology of cannabis 417 
intoxication, which include a variety of cognitive effects such as impairments in memory 418 
(Curran et al., 2002), executive function (Ramaekers et al., 2006), effort-related decision 419 
making (Lawn et al., 2016), and effects on salience processing (Bhattacharyya et al., 2012, 420 
2014). Across the SAL (AI+) network as a whole, the reduction in connectivity produced by 421 
Cann-CBD was not seen in the treatment containing CBD. Regional disruption of the salience 422 
network was also much more evident and widespread in the Cann-CBD treatment, again 423 
suggesting that CBD buffers the user somewhat against the effects of THC on this network. 424 
Disruptions of salience attribution are also thought to play a key role in the development 425 
and maintenance of addiction (Robinson and Berridge, 1993, 2001) and psychosis (Kapur, 426 
2003). This differential effect on the salience network may therefore be a potential neuro-427 
protective mechanism for CBD, by which it prevents the development of such issues with 428 
chronic use. This finding is also consistent with previous behavioural evidence that cannabis 429 
without CBD acutely increases the salience of cannabis cues on an attentional bias task, 430 
while cannabis containing CBD reversed this effect so attention was directed away from 431 
cannabis-cues (Morgan et al., 2010).  432 
 433 
Results have also been reported by Freeman et al. (2017) on a music-listening fMRI task 434 
conducted on the same cohort, in the same scan session, as the resting-state data presented 435 
here. These showed that the Cann-CBD treatment significantly dampened responses to 436 
music in the auditory cortex, and in limbic and striatal regions (amygdala, hippocampus, and 437 
right ventral striatum) while the Cann+CBD treatment had little effect. While it is difficult to 438 
make precise comparisons between the two sets of results, Cann-CBD produced more 439 
disruptions in function than Cann+CBD on this task, and this general pattern is consistent 440 
with the resting-state results presented here. 441 
 442 
A major strength of the present study is that the treatments were administered by vaporiser 443 
inhalation, using the whole plant form rather than synthetic THC and CBD. Doing this in a 444 
placebo-controlled cross-over study gives our findings strong ecological validity and 445 
relevance in a time of increasing liberalisation of cannabis controls across many parts of the 446 
globe. However, given the somewhat exploratory nature of the study and the fact that some 447 
of the results (e.g. the correlations between VAS measures and the PCC) were unpredicted, 448 
the results require replication to be fully substantiated. Replication with a larger sample, 449 
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that included use of a 3 Tesla MRI scanner and further optimised acquisition protocols 450 
would certainly be useful. The use of a larger sample may also enable other factors to be 451 
considered, such as the relationship between the acute response to the drug and the 452 
subjects’ regular usage patterns. Subjects in the current study were somewhat regular, 453 
though not heavy, cannabis users (< 3 times per week, > 4 times in the past year). A more 454 
strictly drug-naïve subject group may have been preferable; however this has to be balanced 455 
against the ethical issues associated with using drug-naïve subjects in pharmacological 456 
studies of this type. Also, subjects who are (semi-)regular users may be more representative 457 
of typical cannabis users than entirely naïve subjects. Other limitations are related to the 458 
study protocol. The resting-state scan was placed towards the end of the imaging protocol; 459 
approximately 70-75 minutes after dosing. Even though subjects still indicated strong 460 
subjective effects of cannabis intoxication after the scan session, it is likely the peak drug 461 
effect occurred somewhat earlier, before the resting state scan. Finally, blood samples were 462 
not acquired in this study protocol, so we have no information about plasma levels of 463 
cannabinoids; future studies should incorporate blood sampling in the protocol to address 464 
this. 465 
 466 
To summarise, both low-CBD and high-CBD strains of cannabis  have widespread effects on 467 
the brain’s major resting state networks, but cannabis devoid of CBD appears to have more 468 
widespread effects, particularly on the DMN (PCC+) and SAL (AI+) networks. In particular, 469 
reductions of connectivity in the SAL (AI+) network produced by the Cann-CBD treatment 470 
were not evident in the presence of CBD. Strong and specific correlations were found only in 471 
the Cann-CBD treatment between PCC function in the DMN (PCC+) and subjective measures 472 
of drug effects, suggesting the PCC is a key region underlying the psychoactivity of THC. A 473 
productive avenue for future work on cannabis would be to examine potential changes in 474 
these networks (and the psychological processes that depend upon them) in a longitudinal 475 
study with individuals who use different strains of cannabis in differing frequencies and 476 
amounts.  477 
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